An international survey covering 101 medical institutions found substantial variation in infection prophylaxis and surveillance practices for patients receiving bispecific antibodies and CAR-T therapies. The report flags inconsistency in how sites operationalize prevention strategies, leaving gaps in standardized infection risk management. In CAR-T and bispecific settings, infection risk depends on patient factors, CRS/ICANS management, and immunosuppression trajectories; inconsistent prophylaxis protocols can translate into uneven outcomes. Survey-based findings typically reflect real-world practice heterogeneity more than evidence gaps, but they still inform where harmonization efforts may be needed. For biotech developers, such variability can complicate cross-trial comparisons and could affect how safety packages are interpreted across geographies and treatment centers. It also underscores that translational control of infection risk is not only a drug property problem but a workflow and policy challenge. The immediate impact is operational: sponsors and clinical networks may push for standardized prophylaxis and surveillance schedules to reduce variation-driven uncertainty.